13G Filing: Matrix Capital Management and Adaptimmune Therapeutics PLC – ADR (ADAP)

Adaptimmune Therapeutics PLC – ADR (NASDAQ:ADAP): David Goel And Paul Ferri’s Matrix Capital Management filed an amended 13D.

You can check out Matrix Capital Management’s latest holdings and filings here.

Please follow Matrix Capital Management (if you aren’t already doing so) to get real-time email alerts whenever we publish an article about Matrix Capital Management or update its stock holdings.

David Goel And Paul Ferri
David Goel And Paul Ferri
Matrix Capital Management

You can access the original SEC filing by clicking here.

Ownership Summary Table

Name Sole Voting Power Shared Voting Power Sole Dispositive Power Shared Dispositive Power Aggregate Amount Owned Power Percent of Class
Matrix Capital Management Company 72,261,066 72,261,066 72,261,066 12.9%
David E. Goel 72,261,066 72,261,066 72,261,066 12.9%
David Goel And Paul Ferri
David Goel And Paul Ferri
Matrix Capital Management

Page 1 of 8 – SEC Filing

SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
SCHEDULE 13G
Under the Securities Exchange Act of 1934
(Amendment No.  )*

Adaptimmune
Therapeutics PLC

(Name of Issuer)

Ordinary
Shares, par value £0.001

(Title of Class of Securities)

00653A107**

(CUSIP Number)

August 31,
2017

(Date of event which requires filing of this statement)
Check the appropriate box to designate the rule pursuant to which this Schedule 13G is filed:
x Rule 13d-1(b)
¨ Rule 13d-1(c)
¨ Rule 13d-1(d)
(Page 1 of 8 Pages)

______________________________

* The remainder of this cover page shall
be filled out for a reporting person’s initial filing on this form with respect to the subject class of securities, and for any
subsequent amendment containing information which would alter the disclosures provided in a prior cover page.

** There is no CUSIP number assigned to
the Ordinary Shares. CUSIP number 00653A107 has been assigned to the American Depositary Shares (“ADSs“) of the
Company. Each ADS represents 6 Ordinary Shares.

The information required in the remainder
of this cover page shall not be deemed to be “filed” for the purpose of Section 18 of the Securities Exchange Act of
1934 (the “Act”) or otherwise subject to the liabilities of that section of the Act but shall be subject to all other
provisions of the Act (however, see the Notes).

Follow Adaptimmune Therapeutics Plc (NASDAQ:ADAP)